Insights from a randomized controlled trial on a digital lifestyle intervention in non-small cell lung cancer survivors following inpatient rehabilitation

Lung Cancer

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)

Clin Lung Cancer

Mitome N, Hamada A, Wakabayashi M, Uozumi T, Horinouchi H, Isaka M, Yotsukura M, Aokage K, Fukuda H, Watanabe SI, Tsutani Y, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group (JCOG)

doi: 10.1016/j.cllc.2026.04.006

Lung Cancer

Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer

Clin Lung Cancer

Zakharia A, Bodner W, Halmos B, Garg M, Gucalp R, Cheng H, Stiles B, Ohri N

doi: 10.1016/j.cllc.2026.03.004

Lung Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lung Cancer

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

Clin Lung Cancer

Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW

doi: 10.1016/j.cllc.2025.10.018

Lung Cancer

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Lancet Oncol

Li Z, Hu J, Chen J, Yu Y, Meng X, Dong X, Hu Y, Ji Y, Liu H, Wang W, Ning F, Zhang Z, Liu C, Zhang Z, Wang Q, Zheng W, Wang H, Qu X, Chen Z, Fan S, Zhang X, Lu S

doi: 10.1016/S1470-2045(26)00090-2

Lung Cancer

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

JAMA Oncol

Socinski MA, Stahel R, Lee DH, Cappuzzo F, Nishio M, Lovly CM, Ozyilkan O, Li Q, Johnson M, Garon EB, Kilickap S, Ferreira da Silva FA, Alatorre-Alexander J, Meng R, Amin R, Matheny C, Troutman S, Wen X, Patil NS, Zou W, Rodriguez-Abreu D

doi: 10.1001/jamaoncol.2026.0818

Lung Cancer

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials

Lung Cancer

Zhou DD, Lord SJ, Lin FP, Cooper WA, Zaheed M, Simes RJ, John T, Lee CK

doi: 10.1016/j.lungcan.2025.108891

Lung Cancer

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial

Lung Cancer

Brosseau S, Etienne H, Peoc'h K, Langlais A, Blanché H, Foucher P, Barlesi F, Domas J, Girard P, Scherpereel A, Dumont P, Derollez M, Quoix E, Debieuvre D, Deleuze JF, Leçon-Malas V, Zalcman G, Westeel V, Mordant P

doi: 10.1016/j.lungcan.2026.109345

Lung Cancer

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial

Lancet Oncol

Zhang L, Zhang X, Wu L, Xing W, Liu C, Zhang P, Chen K, Shi J, Xu S, Zhang X, Dong X, Fang H, Yu X, Gao Y, Li G, Chen Z, Fan S, Zhang X, Cheng Y

doi: 10.1016/S1470-2045(25)00643-6

Related content

A Multi-Institutional Randomized Phase III Trial of Neoadjuvant Chemoimmunotherapy Followed By Surgery Versus Upfront Surgery in Patients With Resectable Clinical Stage II-III Non-Small Cell Lung Cancer: JCOG2317 (NATCH-ICI)

Impact of Consolidation Durvalumab on Local Control Following Chemoradiotherapy for Non-Small Cell Lung Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial

Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial

Tiragolumab Plus Atezolizumab and Chemotherapy for Advanced Nonsquamous Non-Small Cell Lung Cancer: The Phase 3 SKYSCRAPER-06 Randomized Clinical Trial

Clinical impact of TP53 classifications in previously treated advanced driver-negative non-small cell lung cancer: A biomarker analysis of the OAK and POPLAR randomized clinical trials

Club cell secretory protein (CCSP) serum concentration is a prognostic factor after surgical resection of localized non-small cell lung cancer in patients in the IFCT-0302 trial

Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial